US MedTech's Money Maze: Pure Global on New CMS Rules

Last week, the US FDA and CMS announced the TCET pathway, a landmark program to accelerate insurance coverage for innovative medical devices. This move aims to eliminate the notorious "valley of death" where approved devices fail to secure reimbursement, but it also creates new strategic challenges for MedTech manufacturers. This episode of MedTech Global Insights dives into the specifics of this new policy. We analyze how it fundamentally changes the commercialization timeline and what companies must do to capitalize on this opportunity while avoiding the potential pitfalls of early market access. **Featured Case:** Imagine your AI diagnostic software just received FDA Breakthrough Designation. Historically, you'd face another 12-18 months of uncertainty before Medicare might cover it. Now, with the new TCET pathway, coverage could be granted in months. Are you prepared to immediately start the large-scale health economic studies required to make that coverage permanent? This episode tackles that critical question. **Key Questions Answered:** - What are the eligibility criteria for the new TCET pathway? - How does this program change the strategic importance of the FDA's Breakthrough Device Designation? - What kind of real-world evidence will CMS expect companies to collect during the transitional coverage period? - Should companies change their regulatory strategy to prioritize breakthrough designation over other pathways? - How does this impact investment and valuation for MedTech startups? - What are the hidden compliance and data collection burdens associated with this new program? - How can non-US companies leverage this pathway for entering the American market? Contact us at [email protected] or visit https://pureglobal.com/. You can also visit https://pureglobal.ai/ for FREE AI tools and a free medical device database.